Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases.

BioNTech and Moderna at vanguard of new treatment wave - but which is best?

Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Merck

Pfizer

Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.

As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.

Moderna, Inc. (NASDAQ:MRNA ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Evan Wang - Guggenheim Securities Evan Wang [Call Starts Abruptly] Inaugural Health Innovation Conference. I'm Evan Wang, one of the senior biotech analysts at Guggenheim.

Moderna, Inc. (MRNA) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)

Tesla

Spirit Airlines

Here are some of the major companies whose stocks moved on the week's news.

The Score: Spirit, Tesla, Moderna and More Stocks That Defined the Week

Novavax

Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Human Services (HHS).

Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary

Novo Nordisk

SPDR S&P Biotech ETF

With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers.

Trump Taps RFK for HHS: Time to Avoid Biotech?

AstraZeneca

In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.

Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head

Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.

Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department

President Elect Donald Trump called on Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Kennedy is the chairman of anti-vaccine nonprofit Children's Health Defense, and has positioned himself against immunization on several occasions. In response to the nomination, Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA) shares are gapping lower.

2 Vaccine Stocks Gapping Lower on RFK Jr. Nomination

Over the last few months, much has been said and even more has been speculated on when it comes to how the outcome of the 2024 U.S. presidential election will impact the economy, both global and domestic, as well as wider economic conditions.

Shot Down: Vaccine stocks tumble with RFK Jr. as Health Secretary

Moderna stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and Human Services. The post Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS appeared first on Investor's Business Daily.

Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS

President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.

Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS

Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK

Pharma shares hit as Trump picks RFK Jr to lead health department

Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select vaccine skeptic Robert F. Kennedy Jr. as the head of the Department of Health and Human Services.

Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.S. Department of Health and Human Services.

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services.

Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS

Moderna, Inc. (NASDAQ:MRNA ) UBS Global Healthcare Conference November 13, 2024 6:30 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Eliana Merle Good afternoon, everyone. Thank you for joining us at the UBS Healthcare Conference.

Moderna, Inc. (MRNA) UBS Global Healthcare Conference (Transcript)

MUMBAI, India & HYDERABAD, India--(BUSINESS WIRE)-- #COVID19--NIH NIAID will conduct and sponsor the Phase I clinical trial for a computationally-designed mRNA COVID-19 vaccine developed by Indian biotech PopVax.

PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax's Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government's Project NextGen

EMERYVILLE, Calif.--(BUSINESS WIRE)--CRDMO capabilities are tailored for a full range of mRNA applications, including small-scale quantities for personalized cancer vaccines (PCVs).

Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet needle-free technology enhances mRNA vaccine immune response and has been successfully adopted into multiple vaccine development programs.

Poster Presentation at International mRNA Health Conference Showcases Clinical Evidence that PharmaJet® Delivery Systems Enable mRNA Vaccine Delivery

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation. "We are honored to be recognized by BioSpace as the most desirable large employer in the life sciences industry for the fourth year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year

Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis, Purification, Manufacturing & Scale-up), Application (CGT, Vaccines) - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The mRNA synthesis and manufacturing market is expected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024, at a CAGR of 3.4% during the forecast period.

mRNA Synthesis & Manufacturing Market - Global Forecast to 2029

On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News for Moderna Stock (MRNA)